Supplementary Material

Mental illness and COVID-19 vaccination: a multinational investigation of observational & register-based data

Mary M Barker\*, Kadri Kõiv\*, Ingibjörg Magnúsdóttir\*, Hannah Milbourn\*, Bin Wang\*, Xinkai Du\*, Gillian Murphy, Eva Herweijer, Elísabet U Gísladóttir, Huiqi Li, Anikó Lovik, Anna K. Kähler, Archie Campbell, Maria Feychting, Arna Hauksdóttir, Emily E Joyce, Edda Bjork Thordardottir, Emma M. Frans, Asle Hoffart, Reedik Mägi, Gunnar Tómasson, Kristjana Ásbjörnsdóttir, Jóhanna Jakobsdóttir, Ole A. Andreassen, Patrick F. Sullivan, Sverre Urnes Johnson, Thor Aspelund, Ragnhild Eek Brandlistuen, Helga Ask+, Daniel McCartney+, Omid V Ebrahimi+, Kelli Lehto+, Unnur A Valdimarsdóttir+, Fredrik Nyberg+, Fang Fang+

Table of Contents

[Supplementary Table 1: Ethical approvals obtained for each included COVIDMENT cohort study. 2](#_Toc152575381)

[Supplementary Table 2: Key COVID-19 vaccination dates for countries included in the COVIDMENT study population. 2](#_Toc152575382)

[Supplementary Table 3: ICD-10 codes used to define mental illness (in the EstBB-C19 and EstBB-EHR cohorts) and physical comorbidity status (in the EstBB-EHR cohort). 3](#_Toc152575383)

[Supplementary Table 4: Timing of variable definitions in the participating COVIDMENT cohorts. 4](#_Toc152575384)

[Supplementary Table 5: ICD-10 codes used to define mental illness, and types of mental illness, in the Swedish register population. 7](#_Toc152575385)

[Supplementary Table 6: ATC codes used to identify psychiatric medication in the Swedish register population. 7](#_Toc152575386)

[Supplementary Table 7: Distribution of sociodemographic variables in the total included COVIDMENT study population, and in each participating cohort, presented as N (%) or mean [SD]. 8](#_Toc152575387)

[Supplementary Table 8: Uptake of COVID-19 vaccination in each included COVIDMENT cohort, overall and by presence of any mental illness diagnosis, presented as N (%). 10](#_Toc152575388)

[Supplementary Table 9: Meta-analyses heterogeneity measure results in the included COVIDMENT study population. 12](#_Toc152575389)

[Supplementary Table 10: Sensitivity model results (pooled prevalence ratio [PR] (95% CI)), according to the presence of any mental illness diagnosis, in the included COVIDMENT study population. 12](#_Toc152575390)

[Supplementary Table 11: Uptake of COVID-19 vaccination by type of mental illness diagnosis and prescribed psychiatric medication use, in the included Swedish register population, presented as N (%). 13](#_Toc152575391)

[Supplementary Table 12: Stratified model results (prevalence ratio (95% CI)) performed in the Swedish register population, using ‘any mental illness’ and ‘any medication’ as exposure variables, and ‘first dose of COVID-19 vaccination by 30th September 2021’ and ‘second dose of a COVID-19 vaccine by 30th November 2021’ as outcome variables. 13](#_Toc152575392)

[Supplementary Figure 1: Flow chart of COVIDMENT study population. 14](#_Toc152575393)

# **Supplementary Table 1:** Ethical approvals obtained for each included COVIDMENT cohort study.

|  |  |
| --- | --- |
| Cohort | Ethical Approval |
| EstBB cohorts | Estonian Committee on Bioethics and Human Research (1.1–12/1277 and 1.1–12/2860) |
| C-19 Resilience | National Bioethics Committee (NBC no. 20– 073, 21–071) as well as the National Data Protection Authority |
| MAP-19 | Regional Committee for Medical Research Ethics, reference number: 125510 |
| MoBa | Regional Committees for Medical and Health Research Ethics (127708/14140/20138) |
| CovidLife | East of Scotland Research Ethics Service (EoSRES) |
| Omtanke2020 | Ethical approval no. 2020–01785 |

EstBB cohorts (EstBB-C19 = The Estonian Biobank COVID-19 Cohort; EstBB-EHR = The Estonian Biobank electronic health records); C19-Resilience = The Icelandic COVID-19 National Resilience Cohort; MAP-19 = The Norwegian COVID-19, Mental Health and Adherence Project; MoBa = The Norwegian Mother, Father and Child Cohort Study

# **Supplementary Table 2:** Key COVID-19 vaccination dates for countries included in the COVIDMENT study population.

|  |  |  |
| --- | --- | --- |
| Country | Date of first COVID-19 vaccination | Date at which all adults offered at least one dose of a COVID-19 vaccine |
| Estonia | January 20211 | May 20212 |
| Iceland | December 20203 | June 20214 |
| Norway | December 20205 | March 20216 |
| Scotland | December 20207 | June 20218 |
| Sweden | 27thDecember 20209 | August- September 2021\*10-12 |

\*dependent on region of residence

References for Table

1 Uusküla A, Kalda R, Solvak M, Jürisson M, Käärik M, Fischer K, Keis A, Raudvere U, Vilo J, Peterson H, Käärik E. The 1st year of the COVID-19 epidemic in Estonia: a population-based nationwide sequential/consecutive cross-sectional study. Public Health. 2022 Apr;205:150-6

2 Republic of Estonia: Ministry of Social Affairs. Vaccination against COVID-19 will be gradually available to anyone during May. 2021. Accessed: 10 October 2022. Available from: https://www.sm.ee/en/news/vaccination-against-covid-19-will-be-gradually-available-anyone-during-may

3 The Directorate of Health. Iceland’s response. 2022. Accessed: 1 Jan 2023. Available from: https://www.covid.is/sub-categories/iceland-s-response

4 Government of Iceland. COVID-19: Iceland removes all domestic COVID restrictions. 2021. Accessed: 10 October 2022. Available from: https://www.government.is/news/article/2021/06/25/COVID-19-Iceland-removes-all-domestic-COVID-restrictions/

5 Skjesol I, Tritter JQ. The Norwegian way: COVID-19 vaccination policy and practice. Health Policy and Technology. 2022 Jun;11(2%):100635

6 Norwegian Institute of Public Health (NIPH%). AstraZeneca vaccine recommended for all over 18 years of age. 2021. Accessed: 10 October 2022]. Available from: https://www.fhi.no/en/archive/covid-19-archive/covid-19---archived-news-2021/march/astrazeneca-vaccine-recommended-for-all-over-18-years-of-age/

7 Scottish Government. First COVID-19 vaccinations in Scotland take place. 2020. Accessed 2 Jan 2023. Available from: https://www.gov.scot/news/first-covid-19-vaccinations-in-scotland-take-place/

8 Scottish Government. First doses booked in for all adults ahead of schedule. 2021. Accessed: 10 October 2022. Available from:

https://www.gov.scot/news/first-doses-booked-in-for-all-adults-ahead-of-schedule/

9 Krisinformation.se. Covid-19 vaccination begins on 27 December. 2020 10 October 2022]; Available from: https://www.krisinformation.se/en/news/2020/december/vaccination-27-december

10 Sveriges Kommuner och Regioner [SKR]. Regionernas planering avseende vaccinering mot covid-19, delrapport 6 [The planning regarding vaccination against Covid-19 for regions, report 6]. 2021. Accessed: 10 October 2021. Available from: https://skr.se/download/18.5bb54e0c179a302981232fd/1621980314035/Regionernas\_planer%20ing\_%20vaccinering\_covid-19\_delrapport%206.pdf

11 Krisinformation.se. Vecka 26 2021. Accessed: 10 October 2022. 2021. Available from: https://www.krisinformation.se/om-krisinformation/for-myndigheter-och-andra-aktorer/omvarldsbevakning/20212/vecka-26-2021

12 Folkhälsomyndigheten. Över 70 procent av Sveriges vuxna befolkning har fått vaccin mot covid-19. 2021. Accessed: 10 October 2022. Available from: <https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2021/juli/over-70-procent-av-sveriges-vuxna-befolkning-har-fatt-vaccin-mot-covid-19/>

# **Supplementary Table 3:** ICD-10 codes used to define mental illness (in the EstBB-C19 and EstBB-EHR cohorts) and physical comorbidity status (in the EstBB-EHR cohort).

|  |  |  |
| --- | --- | --- |
| Variable | Condition | ICD-10 codes |
| Any mental illness | F00-F99 |
| Physical comorbidity status | Hypertension | I10 |
| Heart disease | I00-I99 (excluding I10) |
| Lung disease | J12-J18, J21-J22, J40-J47, J60-J70, J80-J84, E84.0, Q26.8, Q89.3, M05.1 |
| Chronic renal failure | N17-N19 |
| Cancer | C00-C97 |
| Diabetes | E10-E14 |
| Immunological conditions | B17-B40, D69.0, D69.3, D80-D89, E05.0, E06.3, E10-E14, G04.0, G04.8, G05.8, G35, G36.0-G36.1, G36.8-G36.9, G37.2-G37.5, G37.8-G37.9,G61.0, G70.0, H46.9, L10.0, L10.2, L12.0-L12.3, L12.8-L12.9, M05.0-M05.3, M05.8-M05.9, M06.0-M06.4, M06.8-M06.9, M08.0, M08.2-M08.4, M08.8-M08.9, M31.0, M32, M35.0, N08.5 |

#

# **Supplementary Table 4:** Timing of variable definitions in the participating COVIDMENT cohorts.

|  |  |  |
| --- | --- | --- |
| Variable | Cohort | Timing of variable measurement |
| Exposure variables |
| Diagnosis of any mental illness | EstBB-C19  | Diagnosis from HIF bills (2004 - 26th December 2020) |
| EstBB-EHR  | Diagnosis from HIF bills (2004 - 26th December 2020) |
| C-19 Resilience | Baseline questionnaire (24th April 2020-29th December 2020) |
| MAP-19 | Participants asked about mental illness diagnosis prior to the start of the COVID-19 pandemic in the following follow-up questionnaires: 24th October-12th November 2021, 2nd-14th January 2022, 6th-27th March 2022 |
| MoBa | For females: 1999-2008, 2007-2017; for males: 1999-2008, 2015Responses were collected from the first questionnaire collected at recruitment (during pregnancy) between 1999-2009. Additional cases were collected from self-reported mental illnesses in questionnaires responded to when the children were 8 years old (between 2007 and 2017) for females (mothers), and in 2015 for males (fathers). Participants could answer ”yes” (defined as mental illness diagnosis) or give no response. |
| CovidLife | Baseline questionnaire (COVIDLife1: 17th April -7th June 2020) |
| Omtanke2020 | Baseline questionnaire (9th June 2020-26th December 2020) |
| Anxiety symptoms | EstBB-C19  | C-19 questionnaire (10th May 2020 – 26th December 2020) |
| EstBB-EHR  | NA |
| C-19 Resilience | Baseline questionnaire and monthly follow-up questionnaires (24th April 2020-29th December 2020) |
| MAP-19 | Baseline questionnaire (31st March-7th April 2020) |
| MoBa | Biweekly follow-up questionnaires (11th May 2020-24th May 2020) |
| CovidLife | Baseline questionnaire (COVIDLife1: 17th April -7th June 2020), second questionnaire (COVIDLife2: 21st July - 16th August 2020) |
| Omtanke2020 | Baseline and monthly follow-up questionnaires (9th June 2020-26th December 2020) |
| Depressive symptoms | EstBB-C19  | C-19 questionnaire (10th May 2020 – 26th December 2020) |
| EstBB-EHR  | NA |
| C-19 Resilience | Baseline questionnaire and monthly follow-up questionnaires (24th April 2020-29th December 2020) |
| MAP-19 | Baseline questionnaire (31st March-7th April 2020) |
| MoBa | Biweekly follow-up questionnaires (10th June 2020-23rd June 2020) |
| CovidLife | Baseline questionnaire (COVIDLife1: 17th April -7th June 2020), second questionnaire (COVIDLife2: 21st July - 16th August 2020) |
| Omtanke2020 | Baseline and monthly follow-up questionnaires (9th June 2020-26th December 2020) |
| Outcome variables |
| First dose of a COVID-19 vaccine by 30th September 2021 | EstBB-C19  |  e-Health Record registry immunization notices |
| EstBB-EHR  |  e-Health Record registry immunization notices |
| C-19 Resilience | Monthly follow-up questionnaires (27th May 2021-28th August 2021) |
| MAP-19 | Follow-up questionnaire (4th July-1st August 2021) |
| MoBa | Biweekly follow-up questionnaires (2nd February 2021-30th September 2021) |
| CovidLife | Scotland National COVID-19 vaccination data (8th December 2020 – 30th September 2021) |
| Omtanke2020 | Monthly follow-up questionnaires (27th Dec 2020-30th September 2021) |
| First dose of a COVID-19 vaccine by 18th February 2022 | EstBB-C19  |  e-Health Record registry immunization notices |
| EstBB-EHR  |  e-Health Record registry immunization notices |
| C-19 Resilience | NA |
| MAP-19 | Follow-up questionnaire (2nd-14th January 2022) |
| MoBa | Biweekly follow-up questionnaires (2nd February 2021-18th February 2022) |
| CovidLife | Scotland National COVID-19 vaccination data (8th December 2020 – 30th September 2021) |
| Omtanke2020 | Annual follow-up questionnaire (1st December 2021-18th February 2022) |
| Second dose of a COVID-19 vaccine by 18th February 2022 | EstBB-C19  |  e-Health Record registry immunization notices |
| EstBB-EHR  |  e-Health Record registry immunization notices |
| C-19 Resilience | NA |
| MAP-19 | Follow-up questionnaire (2nd-14th January 2022) |
| MoBa | Biweekly follow-up questionnaires (2nd February 2021-18th February 2022) |
| CovidLife | Scotland National COVID -19 vaccination data (8th December 2020 – 18th February 2022) |
| Omtanke2020 | Annual follow-up questionnaire (1st December 2021-18th February 2022) |
| Covariates |
| Sociodemographic covariates (age, sex) | EstBB-C19  | Based on national personal identification number drawn at recruitment |
| EstBB-EHR  | Based on national personal identification number drawn at recruitment |
| C-19 Resilience | Baseline questionnaire (24th April 2020-29th December 2020) |
| MAP-19 | Baseline questionnaire (31st March 2020-7th April 2020) |
| MoBa | First MoBa questionnaires filled out by females (mothers) and males (fathers) during pregnancy (recruitment 1999-2009) |
| CovidLife | Baseline questionnaire (COVIDLife1: 17th April -7th June 2020) |
| Omtanke2020 | Baseline questionnaire (9th June 2020-26th December 2020) |
| Smoking status | EstBB-C19  | C-19 questionnaire (10th May 2020 – 26th December 2020) |
| EstBB-EHR  | Baseline questionnaire completed upon joining EstBB (up to 26th December 2020) |
| C-19 Resilience | Baseline questionnaire and monthly follow-up questionnaires (24th April 2020-29th December 2020) |
| MAP-19 | NA |
| MoBa | Biweekly COVID-19 follow-up questionnaires (10th June 2020-23rd June 2020) |
| CovidLife | Baseline questionnaire (COVIDLife1: 17th April -7th June 2020) |
| Omtanke2020 | Baseline questionnaire (9th June 2020-26th December 2020) |
| Previous COVID-19 infection | EstBB-C19  | C-19 questionnaire (10th May 2020 – 26th December 2020) |
| EstBB-EHR  | e-Health Record registry (up to 26th December 2020) |
| C-19 Resilience | Baseline questionnaire and monthly follow-up questionnaires (24th April 2020-29th December 2020) |
| MAP-19 | Baseline questionnaire (31st March 2020-7th April 2020) |
| MoBa | Baseline COVID-19 questionnaire and biweekly COVID-19 follow-up questionnaires (31st March 2020-19th December 2020) |
| CovidLife | Electronic Communication of Surveillance in Scotland (ECOSS) data on COVID-19 infections (29th January 2020 – 8th December 2020) |
| Omtanke2020 | Baseline and monthly follow-up questionnaires (9th June 2020-26th December 2020) |
| Physical comorbidity status | EstBB-C19  | C-19 questionnaire (10th May 2020 – 26th December 2020) |
| EstBB-EHR  | Diagnosis from HIF bills (2004 - 26th December 2020) |
| C-19 Resilience | Baseline questionnaire (24th April 2020-29th December 2020) |
| MAP-19 | NA |
| MoBa | For chronic renal failure and immunological conditions: biweekly COVID-19 follow-up questionnaires (5th-18th December 2020)For other conditions: baseline COVID-19 questionnaire (31st March 2020-12th May 2020) |
| CovidLife | Baseline questionnaire (17th April -7th June 2020) |
| Omtanke2020 | Baseline questionnaire (9th June 2020-26th December 2020) |

NA: not applicable (data no available in cohort)

EstBB-C19 = The Estonian Biobank COVID-19 Cohort; EstBB-EHR = The Estonian Biobank electronic health records; C19-Resilience = The Icelandic COVID-19 National Resilience Cohort; MAP-19 = The Norwegian COVID-19, Mental Health and Adherence Project; MoBa = The Norwegian Mother, Father and Child Cohort Study

# **Supplementary Table 5:** ICD-10 codes used to define mental illness, and types of mental illness, in the Swedish register population.

|  |  |
| --- | --- |
| Mental Illness | ICD-10 codes |
| Any mental illness | F10-F19, F20-F29, F32, F33, F40, F41, F43 |
|  |
| Substance use disorder (not including tobacco and alcohol) | F11-F19 (excluding F17) |
| Alcohol use disorder | F10 |
| Tobacco use disorder | F17 |
| Psychotic disorders (schizophrenia and non-affective psychotic disorders) | F20-F29 |
| Depression | F32, F33 |
| Anxiety | F40, F41 |
| Stress-related disorders | F43 |

# **Supplementary Table 6:** ATC codes used to identify psychiatric medication in the Swedish register population.

|  |  |
| --- | --- |
| Psychiatric medication | ATC codes |
| Any psychiatric medication | N06A, N05B, N05C, N05A |
|  |
| Antidepressants | N06A |
| Anxiolytics | N05B |
| Hypnotics/sedatives | N05C |
| Antipsychotics | N05A |

# **Supplementary Table 7:** Distribution of sociodemographic variables in the total included COVIDMENT study population, and in each participating cohort, presented as N (%) or mean [SD].

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Variables | EstBB-C19 (Estonia) (n=5,633) | EstBB-EHR (Estonia) (n=183,332) | C-19 Resilience (Iceland) (n=10,417) | MAP-19 (Norway) (n=3,894) | MoBa (Norway) (n=102,811) | CovidLife (Scotland) (n=4,760) | Omtanke2020 (Sweden) (n=14,451) | Total (N=325,298) |
| Sex |
| Female | 4,240 (75.3%) | 120,436 (65.7%) | 7,115 (68.3%) | 3,002 (77.1%) | 61,973 (60.3%) | 2,989 (62.8%) | 12,057 (83.4%) | 211,812 (65.1%) |
| Male | 1,393 (24.7%) | 62,896 (34.3%) | 3,193 (30.7%) | 883 (22.7%) | 40,838 (39.7%) | 1,767 (37.1%) | 2,394 (16.6%) | 113,364 (34.9%) |
| Other | 0 (0.0%) | 0 (0.0%) | 15 (0.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 15 (0.0%) |
| Missing | 0 (0.0%) | 0 (0.0%) | 94 (0.9%) | 9 (0.2%) | 0 (0.0%) | 4 (0.1%) | 0 (0.0%) | 107 (0.0%) |
| Age group, years |
| 18-29 | 589 (10.5%) | 23,751 (13.0%) | 427 (4.1%) | 1,552 (39.9%) | 0 (0.0%) | 43 (0.9%) | 1,399 (9.7%) | 27,761 (8.5%) |
| 30-39 | 1,426 (25.3%) | 40,308 (22.0%) | 909 (8.7%) | 888 (22.8%) | 8,860 (8.6%) | 358 (7.5%) | 2,053 (14.2%) | 54,802 (16.9%) |
| 40-49 | 1,337 (23.7%) | 37,637 (20.5%) | 1,727 (16.6%) | 660 (16.9%) | 65,942 (64.2%) | 587 (12.3%) | 2,462 (17.0%) | 110,352 (33.9%) |
| 50-59 | 1,259 (22.4%) | 33,892 (18.5%) | 2,736 (26.2%) | 465 (11.9%) | 26,549 (25.8%) | 1,092 (22.9%) | 3,335 (23.1%) | 69,328 (21.3%) |
| 60-69 | 727 (12.9%) | 26,667 (14.5%) | 2,943 (28.3%) | 259 (6.7%) | 1,252 (1.2%) | 1,662 (34.9%) | 2,918 (20.2%) | 36,428 (11.2%) |
| 70 or above | 295 (5.2%) | 21,077 (11.5%) | 1,675 (16.1%) | 70 (1.8%) | 67 (0.1%) | 1,011 (21.3%) | 2,284 (15.8%) | 26,479 (8.1%) |
| Missing | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 141 (0.1%) | 7 (0.2%) | 0 (0.0%) | 148 (0.1%) |
| Mean [SD] age, years  | 46.3 [13.6] | 48.1 [16.2] | 56.1 [13.4] | 36.9 [13.8] | 46.5 [5.3] | 59.4 [12.1] | 52.3 [15.6] | 48.0 [2.9] |
| Previous COVID-19 infection |
| Yes | 912 (16.2%) | 3,772 (2.0%) | 327 (3.1%) | 5 (0.1%) | 2,007 (2.0%) | 83 (1.7%) | 634 (4.4%) | 7,740 (2.4%) |
| No | 4,721 (83.8%) | 67,946 (37.1%) | 10,090 (96.9%) | 3,889 (99.9%) | 100,804 (98.0%) | 4,677 (98.3%) | 13,817 (95.6%) | 205,944 (63.3%) |
| Missing | 0 (0.0%) | 111,614 (60.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 111,614 (34.3%) |
| Smoking status |
| Yes | 773 (13.7%) | 36,035 (19.7%) | 1,486 (14.3%) | 0 (0.0%) | 20,297 (19.8%) | 257 (5.4%) | 1,932 (13.4%) | 60,780 (18.7%) |
| No | 4,542 (80.6%) | 130,074 (70.9%) | 8,918 (85.6%) | 0 (0.0%) | 81,967 (79.7%) | 4,414 (92.7%) | 12,496 (86.5%) | 242,411 (74.5%) |
| Missing | 318 (5.7%) | 17,223 (9.4%) | 13 (0.1%) | 3,894 (100.0%) | 547 (0.5%) | 89 (1.9%) | 23 (0.1%) | 22,107 (6.8%) |
| Chronic physical conditions |
| 0 | 2,574 (45.7%) | 68,730 (37.5%) | 5,735 (55.1%) | 0 (0.0%) | 81879 (79.6%) | 3,546 (74.5%) | 9,250 (64.0%) | 171,714 (52.8%) |
| 1 | 1,805 (32.0%) | 55,229 (30.1%) | 3,099 (29.7%) | 0 (0.0%) | 17169 (16.7%) | 972 (20.4%) | 3,353 (23.2%) | 81,627 (25.1%) |
| ≥2 | 775 (13.8%) | 59,373 (32.4%) | 1,485 (14.3%) | 0 (0.0%) | 3763 (3.7%) | 217 (4.6%)  | 1,218 (8.4%) | 66,831 (20.5%) |
| Missing | 479 (8.5%) | 0 (0.0%) | 98 (0.9%) | 3,894 (100.0%) | 0 (0.0%) | 25 (0.5%) | 630 (4.4%) | 5,126 (1.6%) |

EstBB-C19 = The Estonian Biobank COVID-19 Cohort; EstBB-EHR = The Estonian Biobank electronic health records; C19-Resilience = The Icelandic COVID-19 National Resilience Cohort; MAP-19 = The Norwegian COVID-19, Mental Health and Adherence Project; MoBa = The Norwegian Mother, Father and Child Cohort Study

# **Supplementary Table 8:** Uptake of COVID-19 vaccination in each included COVIDMENT cohort, overall and by presence of any mental illness diagnosis, presented as N (%).

|  |  |  |  |
| --- | --- | --- | --- |
|  | Uptake of first dose of a COVID-19 vaccine by 30th September 2021 | Uptake of first dose of a COVID-19 vaccine by 18th February 2022 | Uptake of second dose of a COVID-19 vaccine by 18th February 2022 |
|  | Yes | No | Total | Yes | No | Total | Yes | No | Total |
| EstBB-C19 (Estonia) | 5,108 (90.7%) | 525 (9.3%) | 5,633 (100.0%) | 5,243 (93.1%) | 390 (6.9%) | 5,633 (100.0%) | 4,950 (94.4%) | 294 (5.6%) | 5,244 (100.0%) |
| Mental illness | 2,796 (90.0%) | 311 (10.0%) | 3,107 (100.0%) | 2,870 (92.4%) | 237 (7.6%) | 3,107 (100.0%) | 2,708 (94.4%) | 162 (5.6%) | 2,870 (100.0%) |
| No mental illness | 2,312 (91.5%) | 214 (8.5%) | 2,526 (100.0%) | 2,373 (93.9%) | 153 (6.1%) | 2,526 (100.0%) | 2,242 (94.4%) | 132 (5.6%) | 2,374 (100.0%) |
| Missing | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| EstBB-EHR (Estonia) | 150,387 (82.0%) | 32,945 (18.0%) | 183,332 (100.0%) | 157,983 (86.2%) | 25,349 (13.8%) | 183,332 (100.0%) | 143,877 (94.4%) | 8,469 (5.6%) | 152,346 (100.0%) |
| Mental illness | 76,855 (80.7%) | 18,353 (19.3%) | 95,208 (100.0%) | 81,038 (85.1%) | 14,170 (14.9%) | 95,208 (100.0%) | 73,634 (94.2%) | 4,541 (5.8%) | 78,175 (100.0%) |
| No mental illness | 73,532 (83.4%) | 14,592 (16.6%) | 88,124 (100.0%) | 76,945 (87.3%) | 11,179 (12.7%) | 88,124 (100.0%) | 70,243 (94.7%) | 3,928 (5.3%) | 74,171 (100.0%) |
| Missing | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| C-19 Resilience (Iceland) | 9,117 (87.5%) | 1,300 (12.5%) | 10,417 (100.0%) | NA | NA | NA | NA | NA | NA |
| Mental illness | 2,460 (85.0%) | 435 (15.0%) | 2,895 (100.0%) | NA | NA | NA | NA | NA | NA |
| No mental illness | 6,446 (88.5%) | 837 (11.5%) | 7,283 (100.0%) | NA | NA | NA | NA | NA | NA |
| Missing | 211 (88.3%) | 28 (11.7%) | 239 (100.0%) | NA | NA | NA | NA | NA | NA |
| MAP-19 (Norway) | 2,529 (78.3%) | 702 (21.7%) | 3,231 (100.0%) | 2,523 (97.2%) | 74 (2.8%) | 2,597 (100.0%) | 2,482 (98.4%) | 41 (1.6%) | 2,523 (100.0%) |
| Mental illness | 425 (73.9%) | 150 (26.1%) | 575 (100.0%) | 503 (95.8%) | 22 (4.2%) | 525 (100.0%) | 492 (97.8%) | 11 (2.2%) | 503 (100.0%) |
| No mental illness | 1,736 (79.6%) | 446 (20.4%) | 2,182 (100.0%) | 2,020 (97.5%) | 52 (2.5%) | 2,072 (100.0%) | 1,990 (98.5%) | 30 (1.5%) | 2,020 (100.0%) |
| Missing | 368 (77.6%) | 106 (22.4%) | 474 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| MoBa (Norway) | 91,424 (89.5%) | 10,704 (10.5%) | 102,128 (100.0%) | 94,500 (91.9%) | 8,311 (8.1%) | 102,811 (100.0%) | 91,442 (96.8%) | 3,058 (3.2%) | 94,500 (100.0%) |
| Mental illness | 13,688 (89.0%) | 1,696 (11.0%) | 15,384 (100.0%) | 14,163 (91.4%) | 1,333 (8.6%) | 15,496 (100.0%) | 13,658 (96.4%) | 505 (3.6%) | 14,163 (100.0%) |
| No mental illness | 77,736 (89.6%) | 9,008 (10.4%) | 86,744 (100.0%) | 80,337 (92.0%) | 6,978 (8.0%) | 87,315 (100.0%) | 77,784 (96.8%) | 2,553 (3.2%) | 80,337 (100.0%) |
| Missing | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| CovidLife (Scotland) | 4,477 (94.1%) | 283 (5.9%) | 4,760 (100.0%) | 4,484 (94.2%) | 276 (5.8%) | 4,760 (100.0%) | 4,461 (100.0%) | 1 (0.0%) | 4,462 (100.0%) |
| Mental illness | 1,151 (93.6%) | 79 (6.4%) | 1,230 (100.0%) | 1,151 (93.6%) | 79 (6.4%) | 1,230 (100.0%) | 1,145 (100.0%) | 0 (0.0%) | 1,145 (100.0%) |
| No mental illness | 3,296 (94.2%) | 203 (5.8%) | 3,499 (100.0%) | 3,303 (94.4%) | 196 (5.6%) | 3,499 (100.0%) | 3,290 (100.0%) | 1 (0.0%) | 3,291 (100.0%) |
| Missing | 30 (96.8%) | 1 (3.2%) | 31 (100.0%) | 30 (96.8%) | 1 (3.2%) | 31 (100.0%) | 26 (100.0%) | 0 (0.0%) | 26 (100.0%) |
| Omtanke2020 (Sweden) | 4,939 (92.7%) | 387 (7.3%) | 5,326 (100.0%) | 14,154 (97.9%) | 297 (2.1%) | 14,451 (100.0%) | 5,227 (98.1%) | 102 (1.9%) | 5,329 (100.0%) |
| Mental illness | 1,666 (91.9%) | 147 (8.1%) | 1,813 (100.0%) | 4,230 (97.4%) | 112 (2.6%) | 4,342 (100.0%) | 1,783 (98.2%) | 32 (1.8%) | 1,815 (100.0%) |
| No mental illness | 3,116 (93.1%) | 232 (6.9%) | 3,348 (100.0%) | 9,634 (98.3%) | 170 (1.7%) | 9,804 (100.0%) | 3,281 (98.0%) | 68 (2.0%) | 3,349 (100.0%) |
| Missing | 157 (95.2%) | 8 (4.8%) | 165 (100.0%) | 290 (95.1%) | 15 (4.9%) | 305 (100.0%) | 163 (98.8%) | 2 (1.2%) | 165 (100.0%) |

# **Supplementary Table 9:** Meta-analyses heterogeneity measure results in the included COVIDMENT study population.

|  |  |
| --- | --- |
|  | Heterogenity (I2) |
| Variable | Any mental illness diagnosis | Anxiety symptoms | Depressive symptoms |
| First dose of a COVID-19 vaccine by 30th September 2021 | 91.4%\*\*\* | 60.7%\* | 63.0%\*\* |
| First dose of a COVID-19 vaccine by 18th February 2022 | 80.0%\*\*\* | 73.7%\*\* | 73.4%\*\* |
| Second dose of a COVID-19 vaccine by 18th February 2022 | 60.7% | 2.0% | 53.4% |

\*\*\*p<0.001; \*\*p<0.01; \*p<0.05

# **Supplementary Table 10:** Sensitivity model results (pooled prevalence ratio [PR] (95% CI)), according to the presence of any mental illness diagnosis, in the included COVIDMENT study population.

|  |  |  |
| --- | --- | --- |
|  | Sensitivity analysis 1 | Sensitivity analysis 2 |
| Pooled PR (95% CI) | I2 | Pooled PR (95% CI) | I2 |
| Outcome |  |  |
| First dose of a COVID-19 vaccine by 30th September 2021 | 0.99 (0.96-1.01) | 91.3%\*\* | 0.99 (0.98-1.00) | 87.1%\*\*\* |
| First dose of a COVID-19 vaccine by 18th February 2022 | 0.99 (0.99-1.00) | 18.2% | 0.99 (0.98-1.00) | 76.8%\* |
| Second dose of a COVID-19 vaccine by 18th February 2022 | NA | NA | 1.00 (0.99-1.00) | 22.5% |

Sensitivity analysis 1: exclusion of cohorts which used electronic health records for the definition of exposure and/or outcome variables

Sensitivity analysis 2: exclusion of individuals with any chronic physical conditions

NA: not applicable (sensitivity analysis 1 was not run for the ‘second dose of a COVID-19 vaccine by 18th February 2022’ as only two cohort could be included)

\*\*\*p<0.001; \*\*p<0.01; \*p<0.05

# **Supplementary Table 11:** Uptake of COVID-19 vaccination by type of mental illness diagnosis and prescribed psychiatric medication use, in the included Swedish register population, presented as N (%).

|  |  |  |
| --- | --- | --- |
|  | First dose of a COVID-19 vaccine by 30th September 2021 | Second dose of a COVID-19 vaccine by 30th November 2021 |
| Yes | No | Total | Yes | No | Total |
| Type of mental illness |
| Substance use disorder\* | 96,666 (73.9%) | 34,122 (26.1%) | 130,788 (100.0%) | 91,661 (94.8%) | 5,005 (5.2%) | 96,666 (100.0%) |
| Alcohol use disorder | 116,345 (79.7%) | 29,664 (20.3%) | 146,009 (100.0%) | 111,715 (96.0%) | 4,630 (4.0%) | 116,345 (100.0%) |
| Tobacco use disorder | 81,827 (81.2%) | 18,896 (18.8%) | 100,723 (100.0%) | 78,968 (96.5%) | 2,859 (3.5%) | 81,827 (100.0%) |
| Psychotic disorders | 99,597 (78.9%) | 26,686 (21.1%) | 126,283 (100.0%) | 96,067 (96.5%) | 3,530 (3.5%) | 99,597 (100.0%) |
| Depression | 178,925 (80.7%) | 42,697 (19.3%) | 221,622 (100.0%) | 172,252 (96.3%) | 6,672 (3.7%) | 178,924 (100.0%) |
| Anxiety | 193,133 (78.7%) | 52,412 (21.4%) | 245,545 (100.0%) | 185,299 (95.9%) | 7,834 (4.1%) | 193,133 (100.0%) |
| Stress-related disorders | 141,489 (78.7%) | 38,344 (21.3%) | 179,833 (100.0%) | 136,120 (96.2%) | 5,369 (3.8%) | 141,489 (100.0%) |
| Type of psychiatric medication |
| Antidepressants | 1,127,619 (87.7%) | 158,523 (12.3%) | 1,286,142 (100.0%) | 1,104,282 (97.9%) | 23,336 (2.1%) | 1,127,618 (100.0%) |
| Anxiolytics | 673,869 (85.9%) | 110,972 (14.1%) | 784,841 (100.0%) | 658,987 (97.8%) | 14,881 (2.2%) | 673,868 (100.0%) |
| Hypnotics/sedatives | 940,546 (88.3%) | 125,222 (11.8%) | 1,065,768 (100.0%) | 922,633 (98.1%) | 17,911 (1.9%) | 940,544 (100.0%) |
| Antipsychotics | 157,254 (81.3%) | 36,252 (18.7%) | 193,506 (100.0%) | 152,536 (97.0%) | 4,718 (3.0%) | 157,254 (100.0%) |

\*Not including alcohol and tobacco use disorders.

# **Supplementary Table 12:** Stratified model results (prevalence ratio (95% CI)) performed in the Swedish register population, using ‘any mental illness’ and ‘any medication’ as exposure variables, and ‘first dose of COVID-19 vaccination by 30th September 2021’ and ‘second dose of a COVID-19 vaccine by 30th November 2021’ as outcome variables.

|  |  |
| --- | --- |
|  | Prevalence Ratio (95% CI) |
| First dose of a COVID-19 vaccine by 30th September 2021 | Second dose of a COVID-19 vaccine by 30th November 2021 |
| Any mental illness | Any medication | Any mental illness | Any medication |
| Sex |
|  Male | 0.97 (0.97-0.97)\*\*\* | 1.02 (1.02-1.02)\*\*\* | 0.99 (0.98-0.99)\*\*\* | 1.00 (1.00-1.00)\*\*\* |
|  Female | 1.00 (0.99-1.00)\*\*\* | 1.03 (1.03-1.03)\*\*\* | 0.99 (0.99-0.99)\*\*\* | 1.00 (1.00-1.00)\*\*\* |
| Chronic physical condition |
|  0 | 0.98 (0.98-0.99)\*\*\* | 1.03 (1.03-1.03)\*\*\* | 0.99 (0.99-0.99)\*\*\* | 1.00 (1.00-1.00)\*\*\* |
|  ≥1 | 0.97 (0.97-0.97)\*\*\* | 1.01 (1.01-1.01)\*\*\* | 0.99 (0.99-0.99)\*\*\* | 1.00 (1.00-1.00)\*\*\* |

\*\*\*p<0.001; \*\*p<0.01; \*p<0.05

# **Supplementary Figure 1:** Flow chart of COVIDMENT study population.A diagram of a group of individuals  Description automatically generated

\*CovidLife (Scotland): only CovidLife participants with linked vaccination data from Generation Scotland were included in the study population.